# Neurorehabilitation Devices Market

> Neurorehabilitation Devices Market Research Report Information By Type (Neuro-Robotic Devices, Wearable Devices, Non-Invasive Stimulators, and Brain-Computer Interfaces), By Application (Brain Stroke, Parkinson's Disease, Multiple Sclerosis, Spinal Cord Injury, Cerebral Palsy, and Schizophrenia), By End-User (Rehabilitation Centers, Hospitals & Clinics, and Home Care) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.8%
- **2025:** USD 1,890 Million
- **2035:** USD 6,980 Million
- **Key Players:** Hocoma (DIH Group), Ekso Bionics, Bionik Laboratories, Medtronic, Abbott Laboratories, BrainCo, Nuvectra Corporation, MindMaze

**Report ID:** MRFR/MED/1642-CR · **Pages:** 115 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** June 05, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurorehabilitation-devices-market-2210

---

## Market Summary

The Global Neurorehabilitation Devices Market size was valued at USD 0.8732 Billion in 2024, and the market is projected to grow from USD 0.9422 Billion in 2025 to USD 2.015 Billion by 2035, registering a CAGR of 7.9% during the forecast period 2025–2035. North America led the market in 2024 with over 45.81% share, generating around USD 0.4 Billion in revenue.
 
Rising neurological disorder prevalence and stroke-related disability are driving demand for neurorehabilitation devices. Aging population and increasing post-acute care needs are accelerating adoption of robotic and AI-enabled rehabilitation systems, improving recovery outcomes and long-term functional independence globally.
 
According to WHO neurological health estimates, neurological disorders affect over 1 in 3 people globally, with stroke alone causing more than 12 million new cases annually and nearly 6.5 million deaths each year, significantly boosting rehabilitation demand.

## Market Drivers

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising prevalence of neurological disorders | ~25% | Global | Long-term (≥4 yr) | [2] |
| Regulatory clearances for brain-computer interfaces | ~18% | North America, Europe | Short-term (≤2 yr) | [4] |
| Advances in robotic-assisted neuro therapy | ~17% | North America, Asia-Pacific | Medium-term (2–4 yr) | [6] |
| Telerehabilitation and remote monitoring expansion | ~14% | Global | Short-term (≤2 yr) | [5] |
| Aging population demographics | ~12% | Europe, Japan | Long-term (≥4 yr) | [15] |
| Government neuroscience funding programs | ~9% | US, EU, China | Medium-term (2–4 yr) | [3] |
| Insurance and reimbursement code expansion | ~5% | North America, Europe | Short-term (≤2 yr) | [7] |

### Rising Prevalence of Neurological Disorders

According to estimates from the World Health Organization, over 1 billion people worldwide suffer from neurological disorders, with stroke alone accounting for 6.5 million fatalities per year [2]. Over 55 million dementia cases were reported globally in the World Alzheimer Report 2021, and by 2030, that number is expected to rise to 78 million [2]. All levels of healthcare are experiencing a steady, non-cyclical demand for cognitive rehabilitation technologies and brain damage recovery tools due to the growing patient population.

### Regulatory Clearances Accelerating BCI Adoption

A new regulatory road for stroke therapy equipment with brain-computer interfaces was created in April 2021 by the FDA's De Novo authorization of the IpsiHand Upper Extremity therapy System [4]. Since then, the European CE marking procedure has been expedited under the MDR 2017/745 framework for brain plasticity therapy devices, and at least seven more neural interface devices have entered the FDA review queue. For qualified neurotechnology devices, these approvals shorten the time-to-market from an average of 5.2 years to about 3.1 years.

### Advances in Robotic-Assisted Neuro Therapy

Robotic exoskeletons and end-effector systems have demonstrated 30–40% improvement in upper-limb motor outcomes compared to conventional therapy, according to a 2023 Cochrane systematic review [6]. Capital investment in neuro-robotics R&D exceeded USD 1.1 billion in 2024 alone, with Hocoma, Bionik Laboratories, and Ekso Bionics expanding manufacturing capacity. Robotic-assisted neuro therapy devices are transitioning from specialized research centers into community rehabilitation hospitals, with installed-base growth of approximately 22% year-over-year in the Asia-Pacific.

### Telerehabilitation Expansion

The pandemic catalyzed a permanent shift toward remote neurorehabilitation delivery. A 2021 study published in PubMed confirmed that telerehabilitation effectively maintained treatment continuity and reduced the global disability burden during COVID-19 lockdowns [5]. By 2024, an estimated 38% of outpatient neurorehabilitation sessions incorporated some form of [remote monitoring](https://www.marketresearchfuture.com/reports/remote-monitoring-control-market-3882), and cognitive rehabilitation technology platforms with built-in video assessment tools now account for USD 290 million in annual revenue.

## Restraints

The restraint impact percentages below are directional estimates of drag on market growth. They are not directly subtracted from the headline CAGR and reflect qualitative expert consensus rather than precise quantitative decomposition.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High device cost and limited reimbursement in LMICs | ~−20% | Asia-Pacific, South America, MEA | Long-term (≥4 yr) | [12] |
| Shortage of trained neurorehabilitation specialists | ~−18% | Global | Medium-term (2–4 yr) | [16] |
| Regulatory fragmentation across jurisdictions | ~−15% | Europe, Asia-Pacific | Medium-term (2–4 yr) | [13] |
| Limited clinical evidence for newer modalities | ~−12% | Global | Short-term (≤2 yr) | [17] |
| Data privacy and cybersecurity concerns | ~−8% | North America, Europe | Short-term (≤2 yr) | [18] |

### High Device Cost and Reimbursement Gaps

The cost of a single neuro-robotic rehabilitation system can range from USD 150,000 to USD 500,000, which is more than most institutions in low- and middle-income nations can afford [12]. Adoption is still concentrated in high-income regions in the absence of established reimbursement structures, which are currently lacking in most of South America, Africa, and Southeast Asia. The addressable market for robotic-assisted neurotherapy in emerging economies is predicted to be 30–35% smaller due to this cost barrier.

### Specialist Workforce Shortage

According to WHO estimates, there is a shortage of over 250,000 neurologists and neurorehabilitation therapists worldwide, with an average of only 0.03 neurologists per 100,000 people in sub-Saharan Africa [16]. Wait times for specialized stroke [rehabilitation equipment](https://www.marketresearchfuture.com/reports/rehabilitation-equipment-market-43440) sessions are often four to six weeks in remote places, even in the United States. Particularly in community-based settings, this manpower bottleneck limits throughput and postpones the practical use of cutting-edge brain injury recovery methods.

### Regulatory Fragmentation

The absence of harmonized global standards for neural plasticity therapy devices forces manufacturers to navigate separate approval pathways in the US (FDA), EU (MDR), Japan (PMDA), China (NMPA), and dozens of smaller agencies [13]. Compliance costs for multi-market registration can reach USD 2–5 million per device, extending payback periods by 18–24 months and discouraging smaller innovators from entering the Neurorehabilitation Devices Market.

## Opportunities

### AI-Powered Personalized Rehabilitation Protocols

Machine learning algorithms analyzing real-time patient movement data can dynamically adjust therapy intensity, enabling cognitive rehabilitation technology to deliver precision medicine at scale. Early clinical trials show AI-optimized protocols improving motor recovery timelines by 25% compared to standardized programs [8]. Companies that embed predictive analytics into their stroke rehabilitation equipment stand to capture premium pricing and long-term subscription revenue

### Home-Use Neurorehabilitation Devices

The pandemic permanently shifted patient expectations toward home-based care. Compact wearable neural stimulators and gamified brain injury recovery tools designed for unsupervised home use represent a largely untapped segment projected to exceed USD 850 million by 2032. Regulatory pathways for over-the-counter neurostimulation are maturing in both the US and EU, creating a direct-to-consumer channel for the Neurorehabilitation Devices Market

### Emerging Market Infrastructure Build-Out

India's Ayushman Bharat program and China's Healthy China 2030 initiative are channeling combined public investment exceeding USD 15 billion into rehabilitation infrastructure [9]. These programs create greenfield demand for affordable neural plasticity therapy devices and robotic-assisted neuro therapy systems adapted for high-patient-volume settings

### Data Monetization and Outcome-Based Payment Models

Neurorehabilitation generates rich longitudinal patient datasets that hold value for pharmaceutical R&D, insurance risk modeling, and clinical trial design. Device manufacturers adopting platform-as-a-service models — where hospitals pay per-outcome rather than per-device — can unlock recurring revenue streams estimated at 2–3× the value of one-time hardware sales Cognitive rehabilitation technology platforms with integrated data analytics are best positioned for this shift.

### Telerehabilitation in Rural and Underserved Regions

Approximately 60% of stroke survivors in rural areas lack access to specialized rehabilitation within the critical first 90 days [5]. Cloud-connected stroke rehabilitation equipment paired with remote specialist supervision can bridge this gap, expanding the serviceable addressable market by an estimated 15–20% in North America and Europe alone

## Future Outlook

### AI and Closed-Loop Adaptive Therapy

Artificial intelligence will fundamentally reshape how the Neurorehabilitation Devices Market delivers patient outcomes over the next decade. Closed-loop systems that continuously adjust stimulation parameters based on real-time EEG and EMG feedback are already in Phase III trials, and commercial deployment is expected by 2028 [8]. These platforms will transform cognitive rehabilitation technology from standardized session-based care into truly personalized, always-learning treatment systems.

### Platform Economics and Device-as-a-Service

Hardware margins in the Neurorehabilitation Devices Market will compress as competition intensifies, pushing manufacturers toward subscription-based models. By 2030, an estimated 40% of stroke rehabilitation equipment revenue will come from software updates, remote monitoring fees, and data analytics services rather than one-time device sales. This shift mirrors broader medtech trends documented by McKinsey, where platform economics increase customer lifetime value by 3–5×.

### Neural Plasticity Research Breakthroughs

The NIH and European Research Council together plan to invest over USD 4.5 billion in neural plasticity research through 2032 [3]. Breakthroughs in understanding synaptic remodeling will directly enhance the efficacy of neural plasticity therapy devices, potentially reducing standard rehabilitation timelines from 12 months to 6–8 months for moderate stroke patients. Brain injury recovery tools incorporating optogenetic stimulation and targeted neurochemical delivery are in early-stage development.

### Global Health Equity and Frugal Innovation

The WHO's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders (2022–2031) explicitly calls for affordable neurorehabilitation access in low-income countries [2]. Frugal innovation — simplified, low-cost versions of robotic-assisted neurotherapy devices designed for community health workers — will open new market segments across sub-Saharan Africa and South Asia, potentially adding USD 400–600 million to the global Neurorehabilitation Devices Market by 2035.

## Segment Insights

### By Product Type

The Neurorehabilitation Devices Market segments by product type into neuro-robotic devices, wearable devices, non-invasive stimulators, and brain-computer interfaces.

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Neuro-Robotic Devices | ~35% share | Hospital capital equipment investment cycles |
| Wearable Devices | CAGR ~16.3% | Home-use and outpatient rehabilitation growth |
| Non-Invasive Stimulators | USD 420 Million (2025) | Outpatient TMS and tDCS adoption |
| Brain-Computer Interfaces | CAGR ~18.2% | Regulatory clearances and clinical evidence expansion |

Neuro-robotic devices remain the revenue backbone of the Neurorehabilitation Devices Market, with systems like upper- and lower-extremity exoskeletons and end-effector platforms deployed in over 4,500 hospitals globally. Robotic-assisted neurotherapy delivers quantifiable, repeatable motion patterns that accelerate motor recovery, and payors increasingly recognize the cost-effectiveness of shorter hospital stays enabled by these devices [6].

Brain-computer interfaces represent the most dynamic frontier. The segment's 18.2% CAGR reflects rapid clinical validation of stroke rehabilitation equipment that translates brain signals into motor commands, bypassing damaged neural pathways. FDA and CE-marked BCI systems are attracting premium reimbursement rates, and cognitive rehabilitation technology incorporating BCI-gamification hybrids is demonstrating superior patient engagement scores in randomized trials [4].

### By End User

The Neurorehabilitation Devices Market segments by end user into hospitals/clinics, cognitive care centers, and others (home care, research institutions).

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals/Clinics | ~52% share | Specialist staffing and capital procurement budgets |
| Cognitive Care Centers | CAGR ~16.1% | Dementia and TBI-focused facility expansion |
| Others (Home Care, Research) | USD 215 Million (2025) | Direct-to-patient device approvals |

Hospitals and clinics dominate because stroke rehabilitation equipment and neuro-robotic systems require supervised clinical environments, skilled therapists, and integrated diagnostic infrastructure. Cognitive care centers are the fastest-growing end-user channel as dedicated facilities for Alzheimer's, dementia, and traumatic brain injury expand across North America and Europe, deploying specialized brain injury recovery tools and neural plasticity therapy devices in multi-disciplinary care teams [11].

## Regional Market Share Analysis

| Region | Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | ~38% share | Reimbursement expansion, BCI innovation |
| Europe | ~29% share | Public stroke rehabilitation programs, MDR compliance |
| Asia-Pacific | CAGR ~16.5% | Infrastructure build-out, aging demographics |
| South America | USD 98 Million (2025) | Public hospital modernization |
| Middle East & Africa | CAGR ~13.2% | Medical tourism, government health initiatives |
| Total | USD 1,890 Million (2025) | — |

The Neurorehabilitation Devices Market exhibits a pronounced geographic concentration, with North America and Europe together accounting for roughly 67% of global revenue in 2025. Asia-Pacific is the decisive growth frontier, driven by demographic pressures and public health investment.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| United States | ~78% of regional share | Medicare CPT code expansion for cognitive rehabilitation technology |
| Canada | CAGR ~13.8% | Provincial stroke rehabilitation equipment funding |
| Mexico | USD 32 Million (2025) | Private hospital chain investment |

The United States drives the Neurorehabilitation Devices Market in North America through a combination of advanced research infrastructure, venture capital activity, and an expansive insurance reimbursement landscape. The NIH's BRAIN Initiative allocated USD 690 million in fiscal year 2024 alone toward neurotechnology development, and CMS introduced new reimbursement codes for brain-computer interface therapy sessions effective January 2025 [3][7].

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | ~24% of regional share | DRG-based neurorehabilitation reimbursement |
| United Kingdom | CAGR ~14.1% | NHS stroke rehabilitation equipment procurement |
| France | USD 78 Million (2025) | National brain injury recovery plan |
| Italy | CAGR ~13.5% | Aging population and public rehabilitation networks |
| Spain | ~7% of regional share | Regional health authority investment |
| Nordic Countries | USD 52 Million (2025) | Digital health integration mandates |
| Russia | CAGR ~11.8% | Federal rehabilitation center expansion |
| Rest of Europe | ~12% of regional share | EU Horizon funding for neural plasticity therapy devices |

Germany anchors European demand through its well-established DRG reimbursement framework that specifically codes for robotic-assisted neuro therapy and non-invasive stimulation sessions. The UK's NHS Long Term Plan earmarked GBP 2.3 billion for stroke care improvements through 2028, directly benefiting brain injury recovery tools manufacturers supplying integrated care pathways [11].

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | ~36% of regional share | Healthy China 2030 rehabilitation spending |
| India | CAGR ~18.4% | Ayushman Bharat infrastructure expansion |
| Japan | USD 68 Million (2025) | Super-aging society rehabilitation demand |
| South Korea | CAGR ~15.7% | National health insurance coverage expansion |
| ASEAN | ~11% of regional share | Medical tourism and private hospital growth |
| Rest of Asia-Pacific | USD 24 Million (2025) | Development bank-funded health projects |

China's State Council rehabilitation services plan aims to establish dedicated neurorehabilitation units in every prefecture-level city by 2030, representing over 330 new facility installations [9]. India's stroke rehabilitation equipment demand is expanding at the fastest country-level pace in the Neurorehabilitation Devices Market, driven by a growing middle class with increasing access to tertiary care hospitals.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | ~58% of regional share | SUS public health system modernization |
| Argentina | CAGR ~12.6% | Private rehabilitation clinic investment |
| Rest of South America | USD 18 Million (2025) | NGO and development bank programs |

Brazil's Unified Health System (SUS) has begun integrating cognitive rehabilitation technology into its standard care protocols for stroke and traumatic brain injury patients, catalyzing procurement of neural plasticity therapy devices across federal and state hospital networks [12].

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | ~31% of regional share | Vision 2030 healthcare diversification |
| UAE | CAGR ~14.9% | Medical tourism and premium hospital networks |
| South Africa | USD 14 Million (2025) | Public-private partnership rehabilitation centers |
| Egypt | CAGR ~12.1% | National neurological disease control program |
| Rest of MEA | ~22% of regional share | International development funding |

Saudi Arabia's Vision 2030 health sector transformation is channeling substantial capital into advanced rehabilitation infrastructure, including dedicated neurorehabilitation centers in Riyadh and Jeddah equipped with robotic-assisted neuro therapy systems [12].

## Competitive Benchmarking

The Neurorehabilitation Devices Market exhibits medium concentration, with the top five players holding an estimated 42–48% combined revenue share. The Herfindahl-Hirschman Index approximates 650–800, indicating a moderately fragmented competitive structure. Competition centers on clinical evidence quality, regulatory portfolio breadth, and integration of cognitive rehabilitation technology into hospital IT ecosystems.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Hocoma (DIH Group) | ~8–11% | Lokomat, Armeo robotic rehabilitation systems | Global leader in robotic-assisted neurotherapy |
| Ekso Bionics | ~6–9% | EksoNR exoskeleton platform | Focused on lower-extremity stroke rehabilitation equipment |
| Bionik Laboratories | ~4–7% | InMotion robotic systems | AI-driven upper-extremity brain injury recovery tools |
| Medtronic | ~5–8% | Deep brain stimulation, neuromodulation | Broad neuromodulation portfolio leveraging scale |
| Abbott Laboratories | ~4–7% | Neuromodulation and brain-computer interface R&D | Cross-selling through cardiovascular and neuro divisions |
| BrainCo | ~3–5% | BCI-enabled prosthetics and rehabilitation | Neural plasticity therapy devices for consumer and clinical |
| Nuvectra Corporation | ~2–4% | Algovita spinal cord stimulation | Niche neurostimulation for pain and motor rehabilitation |
| MindMaze | ~3–5% | MindMotion VR-based cognitive rehabilitation technology | Digital therapeutics and gamified neurorehabilitation |
| Neurolutions | ~2–4% | IpsiHand BCI system | First FDA-cleared BCI stroke rehabilitation device |
| Nexstim | ~2–4% | Navigated TMS systems | Non-invasive stimulator technology for motor mapping |

## Recent News & Developments

- Alliance Equiphoria (April 2022): Alliance Equiphoria sponsored a clinical trial titled "Neurorehabilitation Through Hippotherapy of a Brain Stroke (HippoPostCVA)" to assess and analyze the impact of a hippotherapy program consisting of multiple cycles administered over a total of 22 weeks on the functional and global evolution of post-stroke patients (who had a Ranking 3 at inclusion) during the outpatient rehabilitation phase.
- [MindMaze](https://mindmazetherapeutics.com/) (February 2022): A USD 105 million funding round was secured by MindMaze, a leader in the multibillion-dollar digital neurotherapeutics market, to expedite its plans for global commercial growth, boost ongoing research and development, and streamline the clinical development pipeline of its industry-leading digital therapeutic solutions for a variety of neurological diseases.

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Neurorehabilitation Devices Market — neuro-robotic devices, wearable devices, non-invasive stimulators, brain-computer interfaces |
| Study Period | 2021–2035 |
| CAGR (Forecast) | 14.8% (2026–2035) |
| Market Size — 2025 (Base Year) | USD 1,890 Million |
| Market Size — 2035 (Endpoint) | USD 6,980 Million |
| Fastest Growing Segment | Brain-Computer Interfaces (CAGR ~18.2%) |
| Companies Profiled | 10 (Hocoma, Ekso Bionics, Bionik Laboratories, Medtronic, Abbott, BrainCo, Nuvectra, MindMaze, Neurolutions, Nexstim) |
| Valuation Currency | USD Million |

## Frequently Asked Questions

**Q: How do outcome-based reimbursement models affect purchasing decisions in the Neurorehabilitation Devices Market?**
A: Outcome-based models shift hospital procurement from lowest-cost to highest-efficacy devices, favoring robotic-assisted neuro therapy systems with published clinical evidence. Hospitals increasingly negotiate value-based contracts where payment links to measurable patient improvement benchmarks [7].

**Q: What interoperability challenges exist when integrating brain-computer interfaces with existing hospital EHR systems?**
A: Most BCI manufacturers use proprietary data formats that lack HL7 FHIR compliance, creating integration friction with electronic health records. Hospitals must budget USD 50,000–150,000 for middleware solutions that bridge neural plasticity therapy devices to clinical IT infrastructure [13].

**Q: How does the Neurorehabilitation Devices Market address pediatric neurological rehabilitation needs?**
A: Pediatric neurorehabilitation requires scaled-down robotic exoskeletons and age-appropriate gamified interfaces, a niche that remains underserved. Only three FDA-cleared cognitive rehabilitation technology products currently carry pediatric indications, creating significant whitespace for specialized developers [4].

**Q: What role do clinical registries play in shaping the Neurorehabilitation Devices Market competitive dynamics?**
A: National stroke registries in the US, Germany, and Australia mandate post-discharge rehabilitation tracking, generating real-world evidence that directly influences hospital formulary decisions. Manufacturers whose brain injury recovery tools appear in registry-linked outcome studies gain preferential procurement positioning [6].

**Q: How are insurance coverage gaps affecting adoption of non-invasive stimulators in the Neurorehabilitation Devices Market?**
A: Transcranial magnetic stimulation carries inconsistent coverage across US private payors, with approval rates ranging from 35% to 72% depending on indication. This variability forces clinics to maintain diverse stroke rehabilitation equipment portfolios to manage revenue risk [7].

**Q: What cybersecurity risks are unique to connected neurorehabilitation devices?**
A: Cloud-connected neural plasticity therapy devices transmit sensitive neurological data that, if compromised, could expose cognitive function profiles. The EU's Cyber Resilience Act (2024) now requires mandatory vulnerability assessments for all connected cognitive rehabilitation technology before market placement [18].

**Q: How does the Neurorehabilitation Devices Market outlook change if Alzheimer's disease-modifying therapies gain broader approval?**
A: Approved disease-modifying therapies like lecanemab may extend the treatment window for dementia patients, increasing demand for complementary brain injury recovery tools during the prolonged rehabilitation phase. This therapeutic convergence could add an estimated USD 300–500 million in incremental device demand by 2033 [19].


## Sources

[2] Source: World Health Organization, "Neurological Disorders: Public Health Challenges," WHO, 2023 (www.who.int)
[3] Source: National Institutes of Health, "The BRAIN Initiative — Annual Progress Report," NIH, 2024 (braininitiative.nih.gov)
[4] Source: U.S. Food and Drug Administration, "De Novo Classification — IpsiHand System," FDA, 2021 (www.fda.gov)
[5] Source: Caso, V. et al., "Telerehabilitation in Neurorehabilitation During COVID-19," PubMed, 2021 (pubmed.ncbi.nlm.nih.gov)
[6] Source: Cochrane Library, "Electromechanical-Assisted Training for Walking After Stroke," Cochrane, 2023 (www.cochranelibrary.com)
[7] Source: Centers for Medicare & Medicaid Services, "CY 2025 Physician Fee Schedule Final Rule," CMS, 2024 (www.cms.gov)
[8] Source: Cleveland Clinic, "AI-Driven Neurorehabilitation Clinical Trials Program," Cleveland Clinic, 2024 (my.clevelandclinic.org)
[9] Source: China State Council, "National Rehabilitation Services Development Plan 2025–2030," State Council, 2024 (www.gov.cn)
[11] Source: NHS England, "Long Term Plan — Stroke Programme," NHS, 2023 (www.longtermplan.nhs.uk)
[12] Source: World Bank, "Health Sector Financing in LMICs — Rehabilitation Access Report," World Bank, 2023 (www.worldbank.org)
[13] Source: European Commission, "MDR 2017/745 Implementation Report — Neurotechnology," EC, 2024 (health.ec.europa.eu)
[16] Source: World Health Organization, "Atlas of Neurological Resources," WHO, 2023 (www.who.int)

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurorehabilitation-devices-market-2210*